Treatment of EGFR-Driven Cancer with Fewer Side Effects
AssigneeG1 Therapeutics, Inc.
InventorsJessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs. In addition, methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI are provided wherein an intrinsically EGFR-TKI resistant EGFR-mutant cancer is sensitized to the effects of the EGFR-TKI.
Claims24
A method of treating a human with non-small cell lung cancer (NSCLC) having an epidermal growth factor receptor (EGFR) activating mutation, wherein the mutation is (i) a deletion in exon 19 (ex19del) or (ii) a substitution of leucine with arginine at amino acid 858 (L858R), comprising:
- administering an effective amount of a cyclin dependent kinase 4/6 (CDK4/6) inhibitor of the structure:
- or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
A method of treating a human with non-small cell lung cancer (NSCLC) harboring an EGFR-mutation comprising administering an effective amount of a CDK4/6 inhibitor of the structure:
- or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an EGFR-TKI, wherein the EGFR mutation is associated with sensitivity to EGFR-TKI.
A method of treating a human with non-small cell lung cancer harboring an EGFR activating mutation, wherein the mutation is a substitution of the amino acid leucine with arginine at amino acid 858 (L858R), comprising:
- administering an effective amount of a CDK4/6 inhibitor of the structure:
- or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an EGFR-TKI.
Dependencies are inferred from the claim text.